Cutaneous manifestations of hepatitis C in the era of new antiviral agents

World Journal of Hepatology

Volumn 7, Issue 27, 2015, Pages 2740-2748

  Garcovich, Simone ^a   Garcovich, Matteo ^a   Capizzi, Rodolfo ^a   Gasbarrini, Antonio ^a   Zocco, Maria Assunta ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Chronic liver disease; Extra hepatic manifestation; Hepatitis C virus; Interferon free agents; Lichen planus; Mixed cryoglobulinemia; Skin diseases

Indexed keywords

EID: 84949544092     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i27.2740     Document Type: Review

References (60)

1. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-2212 [PMID: 10524695]
2. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]
3. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis. Am J Med 2015; 128: 950-955 [PMID: 25837517 DOI: 10.1016/j.amjmed.2015.02.017]
4. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012; 379: 348-360 [PMID: 21868085 DOI: 10.1016/S0140-6736(11)60242-0]
5. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 2011; 63: 1748-1757 [PMID: 21400476 DOI: 10.1002/art.30319]
6. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol 2013; 85: 1019-1027 [PMID: 23588727 DOI: 10.1002/jmv.23562]
7. Saadoun D, Resche Rigon M, Pol S, Thibault V, Blanc F, Pialoux G, Karras A, Bazin-Kara D, Cazorla C, Vittecoq D, Musset L, Peltier J, Decaux O, Ziza JM, Lambotte O, Cacoub P. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62: 24-30 [PMID: 25135864 DOI: 10.1016/j.jhep.2014.08.015]
8. Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis 2014; 73: e64 [PMID: 25038237 DOI: 10.1136/annrheumdis-2014-206180]
9. Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med 2015; 127: 413-417 [PMID: 25746436 DOI: 10.1080/00325481.2015.1021660]
10. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-853 [PMID: 22147661 DOI: 10.1002/art.34331]
11. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-334; quiz 504-505 [PMID: 20439619]
12. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-353 [PMID: 20308602 DOI: 10.1182/blood-2009-10-245878]
13. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med 2012; 366: 723-732 [PMID: 22356325 DOI: 10.1056/NEJMcp1103641]
14. Shengyuan L, Songpo Y, Wen W, Wenjing T, Haitao Z, Binyou W. Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 2009; 145: 1040-1047 [PMID: 19770446 DOI: 10.1001/archdermatol.2009.200]
15. Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis 2010; 16: 601-612 [PMID: 20412447]
16. Rübsam K, Schroll A, Weisenseel P, Multhaup S, Ruzicka T, Prinz JC. Lichen planus and hepatitis virus infections: causal association? J Dtsch Dermatol Ges 2011; 9: 464-468 [PMID: 21410879 DOI: 10.1111/j.1610-0387.2011.07619.x]
17. Carbone T, Nasorri F, Pennino D, Donnarumma M, Garcovich S, Eyerich K, Bergamo F, Cavani A. CD56 highCD16 - NK cell involvement in cutaneous lichen planus. Eur J Dermatol 2010; 20: 724-730 [PMID: 20959273 DOI: 10.1684/ejd.2010.1096]
18. Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129: 1088-1099 [PMID: 19242512 DOI: 10.1038/sj.jid.2009.42]
19. Nagao Y, Sata M, Noguchi S, Seno'o T, Kinoshita M, Kameyama T, Ueno T. Detection of hepatitis C virus RNA in oral lichen planus and oral cancer tissues. J Oral Pathol Med 2000; 29: 259-266 [PMID: 10890556 DOI: 10.1034/j.1600-0714.2000.290604.x]
20. Carrozzo M, Quadri R, Latorre P, Pentenero M, Paganin S, Bertolusso G, Gandolfo S, Negro F. Molecular evidence that the hepatitis C virus replicates in the oral mucosa. J Hepatol 2002; 37: 364-369 [PMID: 12175632 DOI: 10.1016/S0168-8278(02)00183-6]
21. Pilli M, Penna A, Zerbini A, Vescovi P, Manfredi M, Negro F, Carrozzo M, Mori C, Giuberti T, Ferrari C, Missale G. Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology 2002; 36: 1446-1452 [PMID: 12447871 DOI: 10.1002/hep.1840360622]
22. el-Kabir M, Scully C, Porter S, Porter K, Macnamara E. Liver function in UK patients with oral lichen planus. Clin Exp Dermatol 1993; 18: 12-16 [PMID: 8440044 DOI: 10.1111/j.1365-2230.1993. tb00957.x]
23. Tanei R, Watanabe K, Nishiyama S. Clinical and histopathologic analysis of the relationship between lichen planus and chronic hepatitis C. J Dermatol 1995; 22: 316-323 [PMID: 7545708]
24. Dalekos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tsianos EV. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10: 933-939 [PMID: 9872615 DOI: 10.1097/00042737-199811000-00006]
25. Manousaridis I, Manousaridis K, Peitsch WK, Schneider SW. Individualizing treatment and choice of medication in lichen planus: a step by step approach. J Dtsch Dermatol Ges 2013; 11: 981-991 [PMID: 23981330 DOI: 10.1111/ddg.12141]
26. Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardi-Bee J, Murphy R. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; 2: CD008092 [PMID: 22336835 DOI: 10.1002/14651858.CD008092.pub2]
27. Galeazzi M, Bellisai F, Manganelli S, Morozzi G, Sebastiani GD. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006; 5: 493-498 [PMID: 16920576 DOI: 10.1016/j.autrev.2006.01.002]
28. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014; 60: 872-884 [PMID: 24280292 DOI: 10.1016/j.jhep.2013.11.013]
29. Elder GH. Update on enzyme and molecular defects in porphyria. Photodermatol Photoimmunol Photomed 1998; 14: 66-69 [PMID: 9638727 DOI: 10.1111/j.1600-0781.1998.tb00014.x]
30. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39: 620-627 [PMID: 12971974 DOI: 10.1016/S0168-8278(03)00346-5]
31. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RW. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-1669 [PMID: 9620340 DOI: 10.1002/hep.510270627]
32. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-238 [PMID: 18166355 DOI: 10.1053/j.gastro.2007.10.011]
33. Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta 2009; 1790: 663-670 [PMID: 18848602 DOI: 10.1016/j.bbagen.2008.09.002]
34. Teubner A, Richter M, Schuppan D, Köstler E, Stölzel U. [Hepatitis C, hemochromatosis and porphyria cutanea tarda]. Dtsch Med Wochenschr 2006; 131: 691-695 [PMID: 16555178 DOI: 10.12659/AJCR.889955]
35. Toll A, Celis R, Ozalla MD, Bruguera M, Herrero C, Ercilla MG. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J Eur Acad Dermatol Venereol 2006; 20: 1201-1206 [PMID: 17062032 DOI: 10.1111/j.1468-3083.2006.01746.x]
36. Fernández I, Castellano G, de Salamanca RE, Colina F, Gómez de la Cámara A, Morán MJ, Muñoz R, Solís-Herruzo JA. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003; 38: 314-319 [PMID: 12737448 DOI: 10.1080/00365520310000672]
37. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008; 53: 815-822 [PMID: 17846887 DOI: 10.1007/s10620-007-9945-7]
38. Azim J, McCurdy H, Moseley RH. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 2008; 14: 5913-5915 [PMID: 18855993]
39. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-994 [PMID: 26025581 DOI: 10.1016/S0140-6736(14)61909-7]
40. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, Tang CH. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46 [PMID: 21543188 DOI: 10.1016/j.jdermsci.2011.03.002]
41. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-1043 [PMID: 21711339 DOI: 10.1111/j.1365-2133.2011.10494.x]
42. Imafuku S, Naito R, Nakayama J. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol 2013; 40: 813-818 [PMID: 23961783 DOI: 10.1111/1346-8138.12240]
43. Taglione E, Vatteroni ML, Martini P, Galluzzo E, Lombardini F, Delle Sedie A, Bendinelli M, Pasero G, Bencivelli W, Riente L. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-372 [PMID: 9972971]
44. Kanada KN, Schupp CW, Armstrong AW. Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. J Eur Acad Dermatol Venereol 2013; 27: 1312-1316 [PMID: 22564047 DOI: 10.1111/j.1468-3083.2012.04563.x]
45. Palazzi C, Olivieri I, D'Amico E, D'Agostino L, Nicolucci A, Pennese E, Petricca A. Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum 2005; 53: 223-225 [PMID: 15818717 DOI: 10.1002/art.21079]
46. Cohen AD, Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010; 220: 218-222 [PMID: 20185894 DOI: 10.1159/000286131]
47. Imafuku S, Nakayama J. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol 2013; 40: 428-433 [PMID: 23414394]
48. Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Gottlieb AB. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 61: 1044-1055 [PMID: 19811848 DOI: 10.1016/j.jaad.2009.03.044]
49. Zanni M, Missale G, Santilli D, Di Nuzzo S. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol 2011; 21: 564-567 [PMID: 21543290 DOI: 10.1684/ejd.2011.1318]
50. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013; 19: 7867-7873 [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867]
51. Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol 2011; 147: 1153-1156 [PMID: 21680760 DOI: 10.1001/archdermatol.2011.178]
52. Kanazawa K, Yaoita H, Tsuda F, Murata K, Okamoto H. Association of prurigo with hepatitis C virus infection. Arch Dermatol 1995; 131: 852-853 [PMID: 7611811 DOI: 10.1001/archderm.1995.01690190108028]
53. Soylu S, Gül U, Kiliç A. Cutaneous manifestations in patients positive for anti-hepatitis C virus antibodies. Acta Derm Venereol 2007; 87: 49-53 [PMID: 17225016 DOI: 10.2340/00015555-0186]
54. Dega H, Francès C, Dupin N, Lebre C, Simantov A, Callot C, Laporte JL, Blot C, Opolon P, Poynard T, Chosidow O. [Pruritus and the hepatitis C virus. The MULTIVIRC Unit]. Ann Dermatol Venereol 1998; 125: 9-12 [PMID: 9747198]
55. Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, van Buuren HR, van Erpecum KJ, Davies NA, Rust C, Engert A, Jalan R, Oude Elferink RP, Beuers U. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56: 1391-1400 [PMID: 22473838 DOI: 10.1002/hep.25748]
56. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T, Yanase M, Tejima K, Nishikawa T, Arai M, Arai H, Omata M, Fujiwara K, Yatomi Y. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007; 41: 616-623 [PMID: 17577119 DOI: 10.1097/01.mcg.0000225642.90898.0e]
57. Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol 2007; 5: 142-151 [PMID: 16919505 DOI: 10.1016/j.cgh.2006.06.010]
58. Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Telaprevir-related dermatitis. JAMA Dermatol 2013; 149: 152-158 [PMID: 23560295 DOI: 10.1001/jamadermatol.2013.938]
59. Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-463 [PMID: 21884670 DOI: 10.1016/j.jhep.2011.08.006]
60. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]